ID   UT-7
AC   CVCL_2233
SY   UT7
DR   BTO; BTO:0000960
DR   CLO; CLO_0009490
DR   CLDB; cl5398
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03472875
DR   BioSample; SAMN10988426
DR   CCLE; UT7_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   CCRID; 1101HUM-PUMC000120
DR   ChEMBL-Cells; CHEMBL3307293
DR   ChEMBL-Targets; CHEMBL614057
DR   Cosmic; 787487
DR   Cosmic; 919130
DR   Cosmic; 975312
DR   Cosmic; 1012128
DR   Cosmic; 1281362
DR   Cosmic; 1465951
DR   Cosmic; 2089659
DR   DepMap; ACH-001230
DR   DSMZ; ACC-137
DR   GEO; GSM743411
DR   GEO; GSM887730
DR   GEO; GSM888825
DR   GEO; GSM1374979
DR   IARC_TP53; 2200
DR   Lonza; 41
DR   PharmacoDB; UT7_1649_2019
DR   Progenetix; CVCL_2233
DR   Wikidata; Q54992037
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1571549;
RX   PubMed=1824823;
RX   PubMed=2217443;
RX   PubMed=7647001;
RX   PubMed=9096695;
RX   PubMed=9195772;
RX   PubMed=9510473;
RX   PubMed=10739008;
RX   PubMed=11021758;
RX   PubMed=11226526;
RX   PubMed=16408098;
RX   PubMed=22460905;
RX   PubMed=23955599;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=UT-7
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Japanese.
CC   Characteristics: CSF2 dependent.
CC   Doubling time: ~36-48 hours (PubMed=1824823); ~70 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.783_919del137; Zygosity=Unspecified (PubMed=1571549).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=2.07%; Native American=0%; East Asian, North=82.57%; East Asian, South=12%; South Asian=0%; European, North=0%; European, South=3.36% (PubMed=30894373).
CC   Derived from sampling site: Bone marrow.
ST   Source(s): CCRID; DSMZ; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 8
ST   D16S539: 10,12
ST   D18S51: 14,17
ST   D19S433: 14,14.2
ST   D21S11: 31.2
ST   D2S1338: 18,23
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 8
ST   D8S1179: 11,15
ST   FGA: 23
ST   Penta D: 9,11
ST   Penta E: 16,17
ST   TH01: 6,9
ST   TPOX: 10
ST   vWA: 14,18 (DSMZ; PubMed=25877200)
ST   vWA: 14,18,19 (CCRID)
DI   NCIt; C7965; Adult acute megakaryoblastic leukemia
DI   ORDO; Orphanet_518; Acute megakaryoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   64Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 23-09-21; Version: 25
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1571549; DOI=10.1182/blood.V79.9.2378.2378;
RA   Sugimoto K., Toyoshima H., Sakai R., Miyagawa K., Hagiwara K.,
RA   Ishikawa F., Takaku F., Yazaki Y., Hirai H.;
RT   "Frequent mutations in the p53 gene in human myeloid leukemia cell
RT   lines.";
RL   Blood 79:2378-2383(1992).
//
RX   PubMed=1824823;
RA   Komatsu N., Nakauchi H., Miwa A., Ishihara T., Eguchi M., Moroi M.,
RA   Okada M., Sato Y., Wada H., Yawata Y., Suda T., Miura Y.;
RT   "Establishment and characterization of a human leukemic cell line with
RT   megakaryocytic features: dependency on granulocyte-macrophage
RT   colony-stimulating factor, interleukin 3, or erythropoietin for growth
RT   and survival.";
RL   Cancer Res. 51:341-348(1991).
//
RX   PubMed=2217443;
RA   Miura Y., Komatsu N., Suda T.;
RT   "Growth and differentiation of two human megakaryoblastic cell lines;
RT   CMK and UT-7.";
RL   Prog. Clin. Biol. Res. 356:259-270(1990).
//
RX   PubMed=7647001; DOI=10.1111/j.1365-2141.1995.tb05591.x;
RA   Ito E., Kasai M., Hayashi Y., Toki T., Arai K., Yokoyama S., Kato K.,
RA   Tachibana N., Yamamoto M., Yokoyama M.;
RT   "Expression of erythroid-specific genes in acute megakaryoblastic
RT   leukaemia and transient myeloproliferative disorder in Down's
RT   syndrome.";
RL   Br. J. Haematol. 90:607-614(1995).
//
RX   PubMed=9096695; DOI=10.1038/sj.leu.2400621;
RA   Drexler H.G., Zaborski M., Quentmeier H.;
RT   "Thrombopoietin supports the continuous growth of cytokine-dependent
RT   human leukemia cell lines.";
RL   Leukemia 11:541-551(1997).
//
RX   PubMed=9195772;
RA   Tohyama K.;
RT   "Human factor-dependent leukemia cell lines.";
RL   Int. J. Hematol. 65:309-317(1997).
//
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11021758; DOI=10.1038/sj.leu.2401891;
RA   Majka M., Rozmyslowicz T., Honczarenko M., Ratajczak J., Wasik M.A.,
RA   Gaulton G.N., Ratajczak M.Z.;
RT   "Biological significance of the expression of HIV-related chemokine
RT   coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic
RT   cell lines.";
RL   Leukemia 14:1821-1832(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000),255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23955599; DOI=10.1038/ng.2731;
RA   Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y.,
RA   Yoshida K., Okuno Y., Bando M., Nakato R., Ishikawa S.,
RA   Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D.,
RA   Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K.,
RA   Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M.,
RA   Nakamaki T., Ishiyama K., Nolte F., Hofmann W.-K., Miyawaki S.,
RA   Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H.,
RA   Haferlach T., Shirahige K., Miyano S., Ogawa S.;
RT   "Recurrent mutations in multiple components of the cohesin complex in
RT   myeloid neoplasms.";
RL   Nat. Genet. 45:1232-1237(2013).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//